This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human VEGF (aa 207-318) Protein, CF
catalog :
298-VS-005/CF
quantity :
5 ug (also 25 ug)
price :
407 USD
citations: 12
| Reference |
|---|
Matsuda A, Fukuda S, Matsumoto K, Saito H. Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol. 2008;38:168-75 pubmed
|
Pan Q, Chathery Y, Wu Y, Rathore N, Tong R, Peale F, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007;282:24049-56 pubmed
|
Ball S, Shuttleworth C, Kielty C. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol. 2007;177:489-500 pubmed
|
Neria F, Caramelo C, Peinado H, Gonzalez Pacheco F, Deudero J, De Solis A, et al. Mechanisms of endothelial cell protection by blockade of the JAK2 pathway. Am J Physiol Cell Physiol. 2007;292:C1123-31 pubmed
|
Lake A, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret G, et al. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem. 2006;281:37844-52 pubmed
|
Narazaki M, Tosato G. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood. 2006;107:3892-901 pubmed
|
Sun J, Phung T, Shiojima I, Felske T, Upalakalin J, Feng D, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A. 2005;102:128-33 pubmed
|
Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45:368-74 pubmed
|
product information
master code :
298-VS/CF
SKU :
298-VS-005/CF
product name :
Recombinant Human VEGF (aa 207-318) Protein, CF
unit size :
5 ug (also 25 ug)
description :
The Recombinant Human VEGF (aa 207-318) Protein, CF from R&D Systems is derived from E. coli. The Recombinant Human VEGF (aa 207-318) Protein, CF has been validated for the following applications: Bioactivity.
target :
VEGF
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 ╡m filtered solution in Acetonitrile and TFA.
conjugate :
Unconjugated
purity :
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
species :
Human
theoretical molecular weight :
14.1 kDa (monomer)
gene symbol :
VEGFA
details of functionality :
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al . (1990) Proc. Natl. Acad. Sci. USA 87 :1323. The ED50 for this effect is 0.75-3.75 ng/mL.
endotoxin note :
<0.01 EU per 1 ╡g of the protein by the LAL method.
top caption :
Recombinant Human VEGF (aa 207-318) Protein Bioactivity
accessionNumbers :
NP_001020541
applications :
Bioactivity
source long :
E. coli -derived human VEGF protein Ala207-Arg318
source short :
E. coli
USD :
407 USD
alt names :
MVCD1, VAS, vascular endothelial growth factor A, Vascular permeability factor, Vasculotropin, VEGFA, VEGF-A, VEGFMGC70609, VPF, VPFvascular endothelial growth factor
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
questions and comments
